Pluri Inc. entered into an Advance Subscription Agreement with Chutzpah Holdings LP on June 14, 2026, receiving $1,250,000 in advance payment for a future financing round expected to be completed by August 14, 2026. Additionally, following the 2026 Annual Meeting of Shareholders, shareholder votes resulted in the non-re-election of Eitan Ajchenbaum to the Board, and the Board subsequently appointed Doron Shorrer to fill the vacancy. Pluri Inc. operates in the biotechnology/life sciences industry, focusing on on-demand cell therapy products.
